MY 12-YEAR BATTLE WITH MDS - By Jane Biehl PhD
I had an article published in 2017 by AAMDSIF and was asked to update everyone. I will briefly reiterate the first part of my journey and then move forward!
patient
Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide
Original Publication Date
Article Source
External Web Content
Key Points Bone marrow transplantation with posttransplantation CY in severe aplastic anemia results in rapid hematopoietic reconstitution. Rates of graft-versus-host-disease-free survival in treatment-naïve and refractory disease compare very favorably to standard therapies.…
“Everything is going to be okay:” Jocelyn’s Story of Aplastic Anemia, PNH, and Survivorship
Before diagnosis, Jocelyn’s life was normal, predictable. She was thriving her senior year in college, studying Public Relations. In 2008, she was working, volunteering, attending classes---all the normal activities for a 20-year-old.
But one day that changed. Extreme fatigue set in, making it difficult to walk a single flight of stairs. At first, she dismissed the fatigue to her rigorous schedule.
Luspatercept-aamt
REBLOZYL® (luspatercept-aamt) is the first erythroid maturation agent (EMA) approved by the US Food and Drug Administration and European Union for the treatment of anemia anemia: (uh-NEE-mee-uh) A condition in which
Luca Malcovati, MD
Institution
IRCCS S. Matteo Hospital Foundation & University of Pavia
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Dr. Malcovati is an Associate Professor of Hematology at the University of Pavia Medical School and with special interest and expertise in myeloid neoplasms, in particular, myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Dr. Malcovati's research group has made a significant contribution to understanding the molecular basis of myeloid neoplasms and to the integration of somatic mutations in the clinical management of patients.